Replies to post #516 on Biotech Ideas

[bladerunner1717]

JSPR was up over 800% this morning, but has fallen back.

The bigger news may come later this quarter.

[quote
Continued progress on the registrational study of JSP191 in older, transplant-eligible patients with AML/MDS: Jasper held a Type B meeting with the FDA during which a review of the trial comparator arm, population, size, statistical assumptions, and primary endpoints were discussed. The Company agreed with the FDA to submit a trial protocol that will allow a potential initiation of a registrational study in AML and MDS patients undergoing stem cell transplant.

Upcoming clinical and corporate milestones:

Initiate a new study of JSP191 as second-line therapy for patients with lower-risk MDS expected to start in the first quarter of 2023

Initiate a registrational study in AML/MDS patients undergoing stem cell transplant in the first quarter of 2023][/quote]

Bladerunner